Pharmacological evaluation in Immune-enhancement of anti-neoplastics
Project/Area Number |
16K08907
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Applied pharmacology
|
Research Institution | International University of Health and Welfare (2017-2018) Kyoto University (2016) |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
鈴木 栄治 京都大学, 医学研究科, 准教授 (00612897)
|
Project Period (FY) |
2016-04-01 – 2019-03-31
|
Project Status |
Completed (Fiscal Year 2018)
|
Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2018: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
Keywords | Oncology / トリプルネガティブ乳癌 / プラチナ製剤 / NK活性 / 細胞性免疫 / 治療効果予測 / 免疫チェックポイント阻害剤 / ホスト因子 / 癌 / 臨床 / 免疫学 / トランスレーショナルリサーチ / 薬理学 |
Outline of Final Research Achievements |
Triple Negative Breast Cancer Is known to have very poor prognosis. We have conducted neoadjuvant platinum-based chemotherapy for over 40 patients and median follow-up period is now over 4 years. We have excellent prognosis for patients we treated, and we are analyzing immunological biomarker in conjunction with pharmacokinetics of platinum.
|
Academic Significance and Societal Importance of the Research Achievements |
トリプルネガティブ乳癌は組織学的高悪性度で早期再発が多く予後不良で、明確な治療標的薬もなく治療に難渋する。更に術前化学療法で病理学的完全反応(pCR)に至らない場合は極めて予後不良である。京都大学にてCDDP含有術前化学療法を行った症例におけるEvent-free survivalは、pCR有無に関わらず同等であり、pCRによって大きな差が認められた非CDDP症例と対照的であった。non pCR症例においてもCDDPが何らかの再発抑制効果持続(NK活性)に寄与していいる可能性が示唆された。今後は免疫チェックポイント阻害剤などとの併用で更なる治療成績向上につなげていきたい。
|
Report
(4 results)
Research Products
(31 results)
-
-
[Journal Article] Pharmacogenomic-pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer2019
Author(s)
Ishiguro H, Ohno S, Yamamoto Y, Takao S, Sato N, Fujisawa T, Kadoya T, Kuroi K, Bando H, Teramura Y, Iwata H, Tanaka S, Toi M
-
Journal Title
Breast Cancer
Volume: Epub ahead of print
Issue: 5
Pages: 0-0
DOI
NAID
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Granulocyte-Colony Stimulating Factor Producing-Metaplastic Carcinoma of the Breast with Significant Elevation of Serum Interleukin-17 and Vascular Endothelial Growth Factor Levels: A Case Report2018
Author(s)
Fukui Y, Kawashima M, Kawaguchi K, Takeuchi M, Hirata M , Kataoka TR, Sakurai T, Masako Kataoka M, Kanao S, Nakamoto Y, Hirata K, Yoshimura M, Yoshikawa K, Ishiguro H, Toi M
-
Journal Title
Int Canc Conf J
Volume: 7(3)
Issue: 3
Pages: 107-13
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
[Journal Article] Effect of dose timing on the blood concentration of lapatinib in patients with breast cancer2017
Author(s)
Ohgami M, Bando H, Ishiguro H, Tsuda M, Toriguchi N, Aogi K, Toi M, Masuda N, Mitsuhashi S, Kurosawa A, Homma M
-
Journal Title
Ann Oncol
Volume: 28
Issue: 11
Pages: 2888-2889
DOI
Related Report
Peer Reviewed
-
[Journal Article] A randomized phase II study of <i>nab</i>-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer2017
Author(s)
Tamura K,Inoue K, Masuda N,Takao S, Kashiwaba M,Tokuda Y,Iwata H,Yamamoto N, Aogi K,Saeki T, Nakayama T,Sato N,Toyama T,Ishida T, Arioka H, Saito M,Ono S, Yamauchi H, Yamada K, Watanabe J,Ishiguro H,Fujiwara Y
-
Journal Title
Cancer Science
Volume: 印刷中
Issue: 5
Pages: 987-994
DOI
NAID
Related Report
Peer Reviewed / Open Access
-
-
-
[Presentation] Prospective Observational Cohort Study of Real World Chemotherapy Sequence for Metastatic Breast Cancer (KBCRN A001: E-SPEC Study)2018
Author(s)
Nakatsukasa K, Kikawa Y, Kotake T, Yamagami K, Tsuyuki S, Yamashiro H, Suwa H, Sugie T, Okuno T, Kato H, Takahara S, Nakayama I, Ogura N, Moriguchi Y, Takada M, Suzuki E, Yoshibayashi H, Ishiguro H, Taguchi T, Toi M
Organizer
ESMO 2018 Congress
Related Report
Int'l Joint Research
-
-
-
[Presentation] Phase 2 study of Pembrolizumab for metastatic triple-negative breast cancer (mTNBC): Japanese Subgroup Results of KEYNOTE 0862017
Author(s)
Hattori M, Tamura K, Mukai H, Miyoshi Y, Masuda N, Suzuki E, Ishiguro H, Ohtani S, Hara F, Shimamoto T, Yamamoto K, Ding Yu, Aktan G, Karantza V, Iwata H
Organizer
ESMO Asia 2017 Congress
Related Report
Int'l Joint Research
-
[Presentation] The Effects of Frozen Gloves and Socks on Paclitaxel-Induced Peripheral Neuropathy Among Patients with Breast Cancer: A Self-Controlled Clinical Trial.2017
Author(s)
Hanai A,Ishiguro H,Sozu T,Tsuda M,Yano I,Nakagawa T,Imai S,Hamabe Y,Toi M,Arai H,Tsuboyama T
Organizer
The 15th International Symposium of Training Plan for Oncology Professiona
Place of Presentation
Sheraton Osaka
Related Report
Int'l Joint Research
-
-
-
[Presentation] Duration of fasting before taking lapatinib is associated with skin toxicity in neoadjuvant treatment of HER2 positive breast cancer : A cohort study from JBCRG-16/Neo-LaTH2016
Author(s)
Tsuda M,Ishiguro H,Toriguchi N,Masuda N,Bando H,Ohgami M,Homma M,Morita S,Yamamoto N,Kuroi K,Takano T,Shimizu S,Toi M
Organizer
SanAntonio Breast Cancer Symposium 2016
Place of Presentation
Henry B Gonzales Convention Center
Year and Date
2016-12-06
Related Report
Int'l Joint Research
-
-
-
-
-
-
-
-
-
-
-